Treating Heart Failure Chronic Heart Failure NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: Table 42: Clinical evidence summary: Mineralocorticoid receptor antagonists versus placebo for heart failure with preserved ejection fraction Outcomes No of Participants (studies) Follow up Quality of the evidence (GRADE) Relative effect Anticipated absolute effects Risk with Placebo Risk difference with Mineralocorticoid receptor antagonist (95% CI) All-cause mortality (time to event) 3445 MODERATEa due to imprecision (from 34 fewer to 12 more) All-cause mortality (dichotomous) 400 VERY LOWa, c due to risk of bias, imprecision Peto Odds Quality of life (Kansas City) Kansas City Cardiomyopathy Questionnaire. Scale from: 0 to 100. LOWc due to risk of bias b The mean quality of life (kansas city) in the intervention groups was Quality of life (EQ-VAS) EQ-VASi . Scale from: 0 to 100. time unclearj LOWc due to risk of bias b The mean quality of life (eq-vas) in the intervention group was (0.27 lower to 1.21 higher) Quality of life (MLWHF). Scale from: 0 to 105. MODERATEc due to risk of bias The mean quality of life (minnesota) in the control groups was The mean quality of life (minnesota) in the intervention groups was (3.54 lower to 3.54 higher) Quality of life (SF-36 Physical Functioning) SF-36 Physical Functioning scale MODERATEc due to risk of bias The mean quality of life (sf-36 physical functioning) in the control groups was The mean quality of life (sf-36 physical functioning) in the intervention groups was (6.61 lower to 2.61 higher) Treating Heart Failure Chronic Heart Failure NICE 2018. All rights reserved. Subject to Notice of rights. 